Medtronic plc a global leader in healthcare technology, announced U.S. Food and Drug Administration (FDA) clearance for its new InPen™ app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera™ continuous glucose monitor (CGM).
Jazz Pharmaceuticals plc announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.
Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the appointment of Louis Denis, M.D. as Chief Medical Officer. Dr. Denis brings more than 30 years of clinical development leadership and oncology expertise to Byondis.
Lunit a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a strategic collaboration with AstraZeneca, a leading pharmaceutical company, to develop AI-powered digital pathology solutions.
Nevro Corp. a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain,announced the publication of new data in Medical Devices: Evidence and Research, which demonstrate the superiority of the Nevro1™ SI Joint Fusion System ("Nevro1").
Boston Scientific Corporation announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Key findings from the study comparing the device to first-line oral anticoagulation (OAC) – including direct oral anticoagulants (DOAC) (95%) and warfarin (5%) – for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented in a late-breaking science session at the American Heart Association's Scientific Sessions 2024, and simultaneously published in The New England Journal of Medicine.
Angels for Change is proud to announce a significant milestone in Project PROTECT, which aims to anticipate and mitigate critical U.S. drug shortages of essential medicines through non-profit partnership.
Centinel Spine®, LLC the leading global medical device company focused exclusively on treating cervical and lumbar spinal disease with the most complete and clinically-proven total disc replacement (TDR) technology platform in the world (prodisc®), announced significant expansion of coverage for lumbar TDR procedures in the Mid-Atlantic region of the U.S.
Avantor, Inc. a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries,announced the opening of its new flagship Bridgewater Innovation Center. The state-of-the-art research and development facility, located in Bridgewater, NJ, is part of Avantor's network of 13 research and innovation centers across the globe.
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce that its most recently FDA-approved magnetic resonance imaging (MRI) agent, VUEWAY® (gadopiclenol) solution for injection, has reached over one million patient injections at over 480 customer sites.